Compare SON & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SON | TNGX |
|---|---|---|
| Founded | 1899 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.1B |
| IPO Year | 2014 | 2020 |
| Metric | SON | TNGX |
|---|---|---|
| Price | $50.64 | $25.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | ★ $59.33 | $44.88 |
| AVG Volume (30 Days) | 870.1K | ★ 3.4M |
| Earning Date | 10-21-2026 | 11-03-2026 |
| Dividend Yield | ★ 4.34% | N/A |
| EPS Growth | ★ 510.30 | 26.89 |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $7,518,753,000.00 | $62,384,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.04 | N/A |
| P/E Ratio | $73.26 | ★ N/A |
| Revenue Growth | 41.72 | ★ 48.29 |
| 52 Week Low | $38.65 | $6.69 |
| 52 Week High | $60.67 | $34.39 |
| Indicator | SON | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 50.57 | 48.18 |
| Support Level | $46.80 | $19.99 |
| Resistance Level | $50.90 | $25.42 |
| Average True Range (ATR) | 1.15 | 1.40 |
| MACD | 0.38 | -0.03 |
| Stochastic Oscillator | 74.45 | 45.84 |
Sonoco Products Co is engaged in the manufacture and supply of consumer and industrial packaging products, offering paper, metal, and plastic packaging solutions across multiple end markets. The company has two reportable segments: Consumer Packaging and Industrial Paper Packaging. The Consumer Packaging segment provides rigid packaging solutions mainly for food, beverage, household, personal care, and pharmaceutical products, while the Industrial Paper Packaging segment produces paper-based packaging materials such as tubes, cores, and protective packaging, supported by paper mills and recycling operations, serving industrial and consumer markets. It generates the majority of its revenue from the Consumer Packaging segment.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.